About 23% and 19% of the spironolactone and placebo groups discontinued treatment, respectively. The majority of treatment ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

GSK PLC GSK shares rallied 1.20% to £15.12 Thursday, on what proved to be an all-around favorable trading session for the ...

Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's ...

GSK PLC closed 11.54% below its 52-week high of £16.79, which the company reached on September 9th.

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

With precious little to report out of Sino-U.S. trade talks in London, investors are ready to pounce on almost any sign a ...

UK pharma major GSK has appointed Sanjay Gurunathan as senior vice president and global head vaccines and infectious disease ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...